Frexalimab is under clinical development by Sanofi and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Frexalimab’s likelihood of approval (LoA) and phase transition for Relapsing Multiple Sclerosis (RMS) took place on 18 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Frexalimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Frexalimab overview
Frexalimab (INX-021) is under development for the treatment of autoimmune diseases including relapsing multiple sclerosis, relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), active systemic lupus erythematosus (SLE) and Sjogren's Syndrome Disease. It is administered through intravenous and subcutaneous route. The therapeutic candidate is a re-engineered antagonist antibody that acts on CD40.
Sanofi overview
Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.
Quick View Frexalimab LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|